Eslam M.H. Ali

518 total citations
19 papers, 389 citations indexed

About

Eslam M.H. Ali is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Eslam M.H. Ali has authored 19 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Organic Chemistry and 8 papers in Computational Theory and Mathematics. Recurrent topics in Eslam M.H. Ali's work include Synthesis and biological activity (10 papers), Melanoma and MAPK Pathways (10 papers) and Computational Drug Discovery Methods (8 papers). Eslam M.H. Ali is often cited by papers focused on Synthesis and biological activity (10 papers), Melanoma and MAPK Pathways (10 papers) and Computational Drug Discovery Methods (8 papers). Eslam M.H. Ali collaborates with scholars based in Egypt, South Korea and United Kingdom. Eslam M.H. Ali's co-authors include Mohammed S. Abdel‐Maksoud, Chang‐Hyun Oh, Usama M. Ammar, Kyung Ho Yoo, Nasser S. M. Ismail, Diaa A. Ibrahim, Rabah A.T. Serya, Dalal A. Abou El Ella, Kyung‐Tae Lee and Mohammed I. El–Gamal and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Medicinal Chemistry and RSC Advances.

In The Last Decade

Eslam M.H. Ali

19 papers receiving 379 citations

Peers

Countries citing papers authored by Eslam M.H. Ali

Since Specialization

Citations

This map shows the geographic impact of Eslam M.H. Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eslam M.H. Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eslam M.H. Ali more than expected).

Fields of papers citing papers by Eslam M.H. Ali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eslam M.H. Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eslam M.H. Ali. The network helps show where Eslam M.H. Ali may publish in the future.

Co-authorship network of co-authors of Eslam M.H. Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Eslam M.H. Ali. A scholar is included among the top collaborators of Eslam M.H. Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eslam M.H. Ali. Eslam M.H. Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	ByeTAC: Bypassing E-Ligase-Targeting Chimeras for Direct Proteasome Degradation 2025 ·Journal of Medicinal Chemistry ·(unknown), Eslam M.H. Ali, (unknown), (unknown), (unknown), Lauren V. Albrecht, Darci J. Trader	6
2	Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML 2025 ·Archiv der Pharmazie ·(unknown), RosaAnna DeFilippis, Amal Kamal Abdel‐Aziz, (unknown), (unknown), (unknown), Omar Abou Khaled, (unknown), (unknown), Eslam M.H. Ali, (unknown), Martin J. McPhillie, Khaled A. M. Abouzid, Rabah A.T. Serya, Maged Henary, Saverio Minucci, Neil P. Shah, Eman M.E. Dokla	2
3	Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers 2023 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Eslam M.H. Ali, Dan Xie, Mostafa H. Ahmed, Carol Beth Post, Darci J. Trader	5
4	Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells 2023 ·European Journal of Medicinal Chemistry ·(unknown), Mohammed S. Abdel‐Maksoud, Eslam M.H. Ali, Usama M. Ammar, Seyed–Omar Zaraei, Md. Mamunul Haque, (unknown), (unknown), Eunice EunKyeong Kim, Jun‐Seok Lee, HaJeung Park, Kwan H. Lee, Mohammed I. El–Gamal, Hee-Kwon Kim, Tamer M. Ibrahim, Chang‐Hyun Oh	8
5	Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAFV600E/p38α kinase inhibitory activity: Synthesis, in vitro assays and in silico study 2022 ·European Journal of Pharmaceutical Sciences ·Eslam M.H. Ali, (unknown), Usama M. Ammar, Seyed–Omar Zaraei, Mohammed S. Abdel‐Maksoud, Mohammed I. El–Gamal, Md. Mamunul Haque, (unknown), Eunice EunKyeong Kim, Jun‐Seok Lee, Kwan H. Lee, Hee-Kwon Kim, Chang‐Hyun Oh	13
6	Identification of Novel Aryl Carboxamide Derivatives as Death-Associated Protein Kinase 1 (DAPK1) Inhibitors with Anti-Proliferative Activities: Design, Synthesis, In Vitro, and In Silico Biological Studies 2022 ·Pharmaceuticals ·Ahmed Elkamhawy, (unknown), Eslam M.H. Ali, Ahmed H.E. Hassan, (unknown), Kyeong Lee, Eun Joo Roh	5
7	Ligand-based design, molecular dynamics and ADMET studies of suggested SARS-CoV-2 M^pro inhibitors 2021 ·RSC Advances ·(unknown), Eslam M.H. Ali, Asmaa M. AboulMagd	10
8	Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity 2021 ·Journal of Medicinal Chemistry ·Mohammed S. Abdel‐Maksoud, Mohammed I. El–Gamal, (unknown), Mahmoud M. Gamal El‐Din, (unknown), (unknown), Usama M. Ammar, (unknown), Eslam M.H. Ali, Kyung‐Tae Lee, Kyung Ho Yoo, Dong Keun Han, Jae Kyun Lee, (unknown), Hong Seok Choi, Young Jik Kwon, Kwan H. Lee, Chang Hyun Oh	25
9	Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors 2021 ·European Journal of Medicinal Chemistry ·Eslam M.H. Ali, (unknown), Mohammed S. Abdel‐Maksoud, Usama M. Ammar, (unknown), Seyed–Omar Zaraei, Mohammed I. El‐Gamal, (unknown), Kyung‐Tae Lee, Hee-Kwon Kim, Kwan H. Lee, Chang‐Hyun Oh	24
10	Design, synthesis, in vitro determination and molecular docking studies of 4-(1-(tert-butyl)-3-phenyl-1H-pyrazol-4-yl) pyridine derivatives with terminal sulfonamide derivatives in LPS-induced RAW264.7 macrophage cells 2021 ·Medicinal Chemistry Research ·(unknown), Mohammed S. Abdel‐Maksoud, Eslam M.H. Ali, Usama M. Ammar, Seyed–Omar Zaraei, Jae‐Min Kim, Su‐Yeon Kim, Kyung‐Tae Lee, Kwan H. Lee, (unknown), Hyun‐Mee Park, Mi‐Jung Ji, Chang‐Hyun Oh	6
11	New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011–2021) focussing on structure–activity relationship (SAR) and docking insights 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Ahmed Elkamhawy, Eslam M.H. Ali, Kyeong Lee	14
12	Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking 2020 ·Bioorganic & Medicinal Chemistry Letters ·Usama M. Ammar, Mohammed S. Abdel‐Maksoud, (unknown), Eslam M.H. Ali, Kyung Ho Yoo, Hong Seok Choi, Jae Kyun Lee, (unknown), Chang‐Hyun Oh	17
13	Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors 2020 ·Bioorganic Chemistry ·Eslam M.H. Ali, Mohammed S. Abdel‐Maksoud, Usama M. Ammar, (unknown), Kyung Ho Yoo, (unknown), Chang‐Hyun Oh	28
14	Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF 2020 ·Bioorganic & Medicinal Chemistry ·Mohammed S. Abdel‐Maksoud, Eslam M.H. Ali, Usama M. Ammar, (unknown), Kyung Ho Yoo, Chang‐Hyun Oh	17
15	Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening 2020 ·Bioorganic Chemistry ·Usama M. Ammar, Mohammed S. Abdel‐Maksoud, Eslam M.H. Ali, (unknown), Kyung Ho Yoo, Chang‐Hyun Oh	21
16	Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor 2020 ·Bioorganic & Medicinal Chemistry ·Eslam M.H. Ali, Mohammed S. Abdel‐Maksoud, Rasha M. Hassan, (unknown), Usama M. Ammar, (unknown), (unknown), Hee-Kwon Kim, Anna Lee, Kyung‐Tae Lee, Chang‐Hyun Oh	28
17	Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors 2019 ·Bioorganic Chemistry ·Mohammed S. Abdel‐Maksoud, Usama M. Ammar, Mohammed I. El–Gamal, Mahmoud M. Gamal El‐Din, (unknown), Eslam M.H. Ali, Kyung Ho Yoo, Kyung‐Tae Lee, Chang‐Hyun Oh	25
18	Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances 2019 ·Bioorganic & Medicinal Chemistry ·Eslam M.H. Ali, Mohammed S. Abdel‐Maksoud, Chang‐Hyun Oh	86
19	Pyrazolo[3,4-d]pyrimidine based scaffold derivatives targeting kinases as anticancer agents 2016 ·SHILAP Revista de lepidopterología ·Nasser S. M. Ismail, Eslam M.H. Ali, Diaa A. Ibrahim, Rabah A.T. Serya, Dalal A. Abou El Ella	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact